Arch_Twitter_Logo.png
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)
06. Mai 2024 06:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
DTC black.png
Discovery Therapeutics Caribe Receives Study May Proceed Letter from FDA to initiate a Phase 3 Clinical Trial of intralesional rhEGF for the treatment of diabetic foot ulcers
30. April 2024 09:00 ET | Discovery Therapeutics Caribe, LLC
FDA approves Discovery Therapeutic Caribe's Phase 3 trial for intralesional rhEGF in severe diabetic foot ulcers.
Arch_Twitter_Logo.png
Arch Therapeutics Provides Year End Operational Update
09. November 2023 06:50 ET | Arch Therapeutics, Inc.
Fiscal year-end AC5 Advanced Wound System update includes Q4 record monthly order volumes, favorable reimbursement decisions and increases in paid claims.
Arch_Twitter_Logo.png
Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program
01. Dezember 2021 07:50 ET | Arch Therapeutics, Inc.
Renowned Expert Dr. Christopher Gauland Shares Insights on Treating DFUs and Success with AC5® Advanced Wound System FRAMINGHAM, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc....
Zhittya Logo.jpg
Zhittya Genesis Medicine Announces It Has Been Approved to Initiate Clinical Trials in Mexico for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
15. Oktober 2020 10:30 ET | Zhittya Genesis Medicine Inc
LAS VEGAS, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (Zhittya), a private company, announces that it will initiate clinical trials in Mexico to test a medical hypothesis that...
SNWV.png
SANUWAVE Health Reports Second Quarter 2019 Financial Results
15. August 2019 08:10 ET | SANUWAVE Health, Inc.
SUWANEE, Ga., Aug. 15, 2019 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB: SNWV) reported financial results for the three months ended June 30, 2019 with the SEC on Wednesday, August 14, 2019....
SNWV.png
SANUWAVE Accelerates Claims Coverage Expansion One Year Ahead of Expectations Due to Recent Positive Change in Reimbursement Coverage
14. August 2019 09:45 ET | SANUWAVE Health, Inc.
SUWANEE, GA, Aug. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) an emerging medical technology company focused on the development and commercialization of...
SNWV.png
SANUWAVE Health Engages Alira Health to Explore Strategic Alternatives and Partnerships in the European Wound Market
20. Mai 2019 09:00 ET | SANUWAVE Health, Inc.
Suwanee, GA, May 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV),  an emerging medical technology company focused on the development and commercialization of...
SNWV.png
SANUWAVE Health Enters the Carolinas, Hires Key Representative and Will Participate in the Modern Wound Care Management Conference April 26-27 in Greensboro, NC
23. April 2019 08:30 ET | SANUWAVE Health, Inc.
Suwanee, GA, April 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) ( www.sanuwave.com) announced they have entered North and South Carolina as their 5th and 6th...
Generex Biotechnology Corp..jpg
Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors Prestigious Diabetic Limb Salvage Conference in Washington D.C.
18. April 2019 13:08 ET | Generex Biotechnology Corp.
Inventor Dr. Lois Chandler, PhD Presents Excellagen® Clinical Trial Data Demonstrating Rapid Healing of Diabetic Neuropathic Foot Ulcers MIRAMAR, FL, April 18, 2019 (GLOBE NEWSWIRE) -- via...